BioCentury
ARTICLE | Company News

ImmunoForge gets rights to PB1023 from PhaseBio

April 19, 2019 5:13 PM UTC

PhaseBio granted ImmunoForge exclusive, worldwide rights to develop and commercialize PB1023 for all indications except diabetes, obesity and non-alcoholic steatohepatitis (NASH).

ImmunoForge Co. Ltd. (Seoul, South Korea) will develop the compound for serious sarcopenia-related diseases...

BCIQ Company Profiles

PhaseBio Pharmaceuticals Inc.